Presentations by Event

Presented at ID Week, New Orleans, October 2016

Microbiological Cure Rates and Antimicrobial Susceptibility of Neisseria gonorrhoeaeto ETX0914 (AZD0914) in a Phase II Treatment Trial for Urogenital Gonorrhea

Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center, ID Week 2016

Program(s): zoliflodacin (etx0914)

Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase InhibitorETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014

Kenneth Lawrence, ID Week 2016

Program(s): etx2514

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Program(s): etx2514

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016

Program(s): etx2514

Presented at ASM Microbe, Boston, June 2016

A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea

Adam Shapiro, ASM Microbe 2016

Addressing the Evolving Challenge of Beta-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes

Ruben Tommasi, ASM Microbe 2016

Program(s): etx2514

In Vitro and In Vivo Efficacy of the Novel Beta-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii

John O’Donnell, ASM Microbe 2016

Program(s): etx2514

ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D β–lactamases, for the Treatment of Gram-negative Infections

Adam Shapiro, ASM Microbe 2016

Program(s): etx2514

Presented at The Boston Area Antimicrobial Research Network, Cambridge, June 2016

Challenges and Opportunities in Drug Discovery

Alita Miller, Boston Area Antimicrobial Research Network 2016